Biotech News

Aprea Therapeutics to Present at October Conferences

Aprea Therapeutics (APRE)Aprea TherapeuticsConference / presentation

Company to participate in 2026 Maxim Growth Summit (October 14) and Regional Biotechnology Conference (October 15) DOYLESTOWN, Pa., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on

Related news

APREAprea Therapeutics2026-11-20 14:00 EST

Aprea Therapeutics Announces Interim Results From the Ongoing First-in-human Phase 1 Study of WEE1 Inhibitor APR-1051 in Patients with Advanced Solid Tumors (ACESOT-1051) at the 38th EORTC-NCI-AACR Symposium in Barcelona

APREAprea Therapeutics2026-11-05 21:05 EST

Aprea Therapeutics to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference

KURAKura Oncology2026-11-13 17:33 EST

Kura Oncology to Participate in Two Investor Conferences in November

CGEMCullinan Therapeutics, Inc.2026-11-04 14:14 EST

Cullinan Therapeutics Announces Presentations for CLN-049, a FLT3 T Cell Engager, and Velinotamig, a BCMA T Cell Engager, at the 68th ASH Annual Meeting

EXELExelixis2026-11-03 21:05 EST

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November

CHRSCoherus BioSciences, Inc.2026-10-27 13:30 EST

Coherus to Participate in Upcoming Investor Conferences

PRLDPrelude Therapeutics2026-10-16 20:01 EST

Prelude Therapeutics to Participate in the Chardan Healthcare Conference

TEVATeva Pharmaceutical Industries2026-11-20 21:30 EST

Teva to Present at the 9th Annual Evercore Healthcare Conference, the Piper Sandler 38th Annual Healthcare Conference and Citi’s 2026 Global Healthcare Conference

URGNUroGen Pharma2026-11-03 13:00 EST

UroGen Pharma to Present at the Guggenheim Securities 3rd Annual Healthcare Innovation Conference

CHRSCoherus BioSciences, Inc.2026-10-14 20:30 EST

Coherus Oncology to Host Webcast to Disclose Interim Tagmokitug Clinical Data on October 28, 2026

Aprea Therapeutics

DNA Damage Response Oncology Aprea Therapeutics develops precision medicines that exploit vulnerabilities in cancer-cell DNA replication and repair. Its programs target biomarker-defined tumors while seeking to limit effects on healthy cells. APR-1051 APR-1051 is a selective oral WEE1 inhibitor in the Phase 1 ACESOT-1051 study for...

Recent company news

Stock data

Close
0.49 USD
Market cap
9.46M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States